CrushSCI.com
125.7平均天数
111中位天数
2最短天数
296最长天数
1402025发文量

Paper Review Records

全部论文审稿周期

27 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接

93 天

Pharmacokinetic Interaction Between Eperisone and Ojeok‐San in Healthy Subjects

作者
Do Hoon Keum; Minkyu Choi; Kyoung Hoon Mo; Sukyong Yoon; Min Soo Park; Young Woo Kim; Won‐Yung Lee; Choon Ok Kim展开收起
作者单位
1. Department of Clinical Pharmacology Severance Hospital Yonsei University Health System Seoul Republic of Korea; 2. Department of Pharmaceutical Medicine and Regulatory Sciences Colleges of Medicine and Pharmacy Yonsei University Incheon Republic of Korea; 3. Department of Pediatrics Yonsei University College of Medicine Seoul Republic of Korea; 4. School of Korean Medicine Dongguk University Gyeongju Republic of Korea; 5. School of Korean Medicine Wonkwang University Iksan Republic of Korea展开收起
PDF源文件 DOI 网页
111 天

Pharmacokinetic and Bioequivalence of Mirtazapine Orally Disintegrating Tablets: A Randomized, Crossover Study

作者
Kai Bin Liew; Kar Ming Yee; Jeyashanthini Nalaiya; Atiqah Amran; Khairil Aswad Othman展开收起
作者单位
1. Department Faculty of Pharmacy University of Cyberjaya (UoC). Cyberjaya Selangor Malaysia; 2. Formulation and R&D Technologies Duopharma Innovation Sdn. Bhd. Shah Alam Selangor Malaysia; 3. Questra Bio‐Clinical Research Centre Questra Clinical Research Sdn. Bhd., Permatang Pauh Pulau Pinang Malaysia展开收起
PDF源文件 DOI 网页
175 天

A Dose‐Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of HP501 in Male Chinese Gout Patients with Hyperuricemia

作者
Longxia Chen; Ruilin Ding; Yuanwei Chen; Xinghai Li; Tengqiong Xiong; Hong Chen; Xiaojing Hu; Yi Zhou; Feng Jiang; Qing Peng展开收起
作者单位
1. Institute of Drug Clinical Trial/GCP Center The Affiliated Hospital of Southwest Medical University Luzhou China; 2. Hinova Pharmaceuticals Inc. Chengdu China; 3. Department of Cardiology The Affiliated Hospital of Southwest Medical University Luzhou China展开收起
PDF源文件 DOI 网页
241 天

A First‐in‐Japanese Phase 1, Double‐Blind, Placebo‐Controlled, Parallel‐Cohort Study of Sefaxersen, an Antisense Oligonucleotide Targeting Complement Factor B, in Healthy Participants

作者
Takakazu Sato; Hiroyuki Fukase; Takaaki Ishida; Arisa Karasawa展开收起
作者单位
1. Chugai Pharmaceutical Co., Ltd. Tokyo Japan; 2. Clinical Research Hospital Tokyo Japan展开收起
PDF源文件 DOI 网页
277 天

Pharmacokinetic and Pharmacodynamic Bio‐Similarity of ADL‐018 to Innovator Omalizumab: A Randomized Study in Healthy Adults

作者
Sunil Soitawala; Hiren Prajapati; Hiren Mehta; Pawan Kumar Singh展开收起
作者单位
1. Clinical Research Department Veeda Clinical Research Ltd. Mehsana Gujarat India; 2. Clinical Research Department Veeda Clinical Research Ltd. Ahmedabad Gujarat India; 3. Clinical Affairs/Biometrics Department Veeda Clinical Research Ltd. Ahmedabad Gujarat India; 4. Kashiv Biosciences, LLC Ahmedabad Gujarat India展开收起
PDF源文件 DOI 网页
126 天

An Open‐Label Study Investigating the 5‐HT 2A Receptor Occupancy of Remlifanserin (ACP‐204) With the PET Radioligand [ 18 F]Altanserin in Healthy Male Participants

作者
Ethan S. Burstein; Christine Sandiego; Brian Raether; Xiaoshu Feng; Bryan Dirks; Mona Darwish; Peter Zhang; David S. Russell; Eugenii A. Rabiner; Sanjeev Pathak展开收起
作者单位
1. Acadia Pharmaceuticals Inc. San Diego CA USA; 2. Perceptive Discovery New Haven CT USA; 3. Acadia Pharmaceuticals Inc. Princeton NJ USA; 4. Perceptive Discovery London UK展开收起
PDF源文件 DOI 网页

Expert Matching · Case Demo

把投稿要求,转成可验证的期刊方案

说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。

我们会在半小时内回复。

CrushSCI 在线

客户询问

我是环境工程专业,需要一篇 SCI,希望 3 个月内见刊。没有基金,也没有大牛挂名,可以投哪些期刊?

CrushSCI回复

可以。先按 90 天时限做可行性筛选,同步查找无基金、无知名作者挂靠的典型论文案例,作为选刊依据。重点核对研究质量与期刊 scope。

拟题建议
《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》

样本口径2026 年最近 5 篇有效论文样本

平均审稿59.6 天

中位数65 天

Contact CrushSCI

联系 CrushSCI

留下手机号或微信号,我们将与你确认学术润色、结构优化或一对一辅导咨询需求。

我们会在半小时内回复。

当前选择:学术咨询服务

预留联系方式

也可以直接发送邮件至 leader@crushsci.com

手机号和微信号至少填写一项,仅用于本次咨询联系,不会公开。